Frequencies of adverse events following COVID-19 vaccination in patients with Systemic Lupus Erythematosus Erythematosus in a referral center in Asuncion-Paraguay
Abstract
The aim of this study is to determine the frequency of adverse events of COVID-19 vaccination in patients with SLE who are attended at referral medical centers in Paraguay.
This is an observational, cross-sectional, descriptive study. Fifty-two patients with SLE who received at least one dose of anticovid vaccine were included. Of which 100% received the first dose, 92.3% the second dose and 15.38% the third dose; 44.6% received SputnikV; 16% Moderna; 12.5% Pfizer, 7.1% AstraZeneca, 3.6% Covaxin and 2.1% Hayat Vax, 8 patients received their third dose corresponding to 3 from Pfizer, 3 from Moderna, 2 from AstraZeneca.
In the 108 doses applied, a total of 43 adverse events were recorded, 95.3% within the first 5 days and the rest at 5 days. A total of 51.2% presented the adverse event after the first dose, 39.5% after the second dose and 9.3% after the third dose. The mean duration of symptoms was 2.3 days ±1.4.
The most important adverse effect was pain at the injection site, followed by fever and fatigue. Exacerbation of SLE was also recorded as an adverse event in 8.3%. Mild adverse effects were recorded, it is concluded that vaccination against covid 19 is safe for patients with SLE.
Downloads
References
(2) Ministerio de Salud Pública y Bienestar Social. Programa Ampliado de Inmunizaciones PAI. Paraguay - Vacuna [Internet]. 2020 [cited 2021 Aug 20]. Available from: http://pai.mspbs.gov.py/article/ vigilanciaesavi
(3) CDC. (2021, agosto 6). Posibles efectos secundarios después de vacunarse contra el COVID-19. 2021 [cited 2021 Aug 22] Disponible en: https://espanol.cdc.gov/ coronavirus/2019-ncov/vaccines/ expect/after.html
(4) Ser.es. Reumatólogos aconsejan vacunarse frente a la COVID-19 con cualquier vacuna disponible [Internet] 2021 [citado el 20 de agosto de 2021]. Disponible en: https://www.ser.es/reumatologos- aconsejan-vacunarse-frente-a-la-covid-19-con-cualquier-vacuna- disponible/
(5) Segura V. Salud Familiar y Comunitaria Inmunización Integral de la Familia [Internet]. Paho.org. [citado el 20 de agosto de 2021]. Disponible en: https://www.paho.org/hq/dmdocuments/2009/H1N1_ GuiaVigil_ESAVI_oct2009_s.pdf
(6) Cartas US, Núñez VLA, Obregón MDÁ, Chávez JMH, Bejarano SJC. Relación entre tiroiditis autoinmune y lupus eritematoso sistémico. Rev Cuba Reumatol. 2020;22(1):1-11.
(7) Graña D, Vargas A, Bérez A, Goñi M, Danza A. Esclerosis sistémica: forma de presentación y manejo terapéutico. Experiencia de un grupo de trabajo en Enfermedades Autoinmunes Sistémicas. Rev Urug Med Interna [Internet]. 17 de marzo de 2018 [citado 15 de abril de 2022];3(1). Disponible en: http://www.medicinainterna.org. uy/wp-content/uploads/2018/03/Rumi_N°1_2018_pgs15-22.pdf
(8) Mussano E, Onetti L, Cadile I, Werner M, Ruffin A, Buliubasich S, et al. Lupus eritematoso sistémico: datos sociodemográficos y su corre- lación clínico-analítica en un hospital universitario. Rev Argent Reumatol. septiembre de 2019;30(3):5-12.
(9) Flores Aguilar L, Roque Quezada JC, Flores Aguilar L, Roque Quezada JC. Lupus Eritematoso Sistémico Infantil: características neuropsiquiátricas y factores pronóstico en su transición a la adultez. Andes Pediatr. 2022;(AHEAD):0-0.
(10) Papagoras C, Fragoulis GE, Zioga N, Simopoulou T, Deftereou K, Kalavri E, et al. Better outcomes of COVID-19 in vaccinated com- pared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2021;221-539.
(11) Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022;81(5):695–709.
(12) Higgins V, Fabros A, Kulasingam V. Quantitative measurement of Anti-SARS-CoV-2 Antibodies: Analytical and clinical evaluation. J Clin Microbiol. 2021;59(4):1098–9.
(13) James D, Jena A, Bharath PN, et al. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A syste- matic review and meta-analysis [published online ahead of print, 2022 Mar 22]. Dig Liver Dis. 2022;S1590-8658(22)00210-9. doi:10.1016/j.dld.2022.03.005
(14) Taborda HS, Salcedo DCD, Guadarrama JDS. Efectos adversos post-aplicación de vacunas COVID 19 en estudiantes del área de la salud de la costa atlántica colombiana. Dilemas Contemp Educ Política Valores [Internet]. 1 de enero de 2022 [citado 15 de abril de 2022]; Disponible en: https://dilemascontemporaneoseduca- cion-politicayvalores.com/index.php/dilemas/article/view/3153
(15) Cosentino V, Larroude MS, Schneeberger E, Infectología (SADI) G de expertos de la SA de, Nacinovich F. Consenso de recomen- daciones de vacunas en adultos con enfermedades reumáticas inflamatorias crónicas autoinmunes. Rev Argent Reumatol. 1 de marzo de 2022;33(1Sup):1-24.
(16) Cairoli E, Espinosa G. Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre. Med Clínica. 2021;157(5):247-52.
(17) FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting [Internet]. 2020. Disponible en: https:// www.fda.gov/media/144434/download
Copyright (c) 2022 Paraguayan Journal of Rheumatology
This work is licensed under a Creative Commons Attribution 4.0 International License.
